Cargando…
Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279813/ https://www.ncbi.nlm.nih.gov/pubmed/34277418 http://dx.doi.org/10.3389/fonc.2021.674083 |
_version_ | 1783722520744034304 |
---|---|
author | Hernandez Vargas, Servando Lin, Christie Tran Cao, Hop S. Ikoma, Naruhiko AghaAmiri, Solmaz Ghosh, Sukhen C. Uselmann, Adam J. Azhdarinia, Ali |
author_facet | Hernandez Vargas, Servando Lin, Christie Tran Cao, Hop S. Ikoma, Naruhiko AghaAmiri, Solmaz Ghosh, Sukhen C. Uselmann, Adam J. Azhdarinia, Ali |
author_sort | Hernandez Vargas, Servando |
collection | PubMed |
description | Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer removal. As a result, the introduction of technologies that enhance the ability to visualize tumors in the operating room represents a pressing need. Such technologies have the potential to revolutionize the surgical standard-of-care by enabling real-time detection of surgical margins, subclinical residual disease, lymph node metastases and synchronous/metachronous tumors. Fluorescence-guided surgery (FGS) in the near-infrared (NIRF) spectrum has shown tremendous promise as an intraoperative imaging modality. An increasing number of clinical studies have demonstrated that tumor-selective FGS agents can improve the predictive value of fluorescence over non-targeted dyes. Whereas NIRF-labeled macromolecules (i.e., antibodies) spearheaded the widespread clinical translation of tumor-selective FGS drugs, peptides and small-molecules are emerging as valuable alternatives. Here, we first review the state-of-the-art of promising low molecular weight agents that are in clinical development for FGS; we then discuss the significance, application and constraints of emerging tumor-selective FGS technologies. |
format | Online Article Text |
id | pubmed-8279813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82798132021-07-15 Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents Hernandez Vargas, Servando Lin, Christie Tran Cao, Hop S. Ikoma, Naruhiko AghaAmiri, Solmaz Ghosh, Sukhen C. Uselmann, Adam J. Azhdarinia, Ali Front Oncol Oncology Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer removal. As a result, the introduction of technologies that enhance the ability to visualize tumors in the operating room represents a pressing need. Such technologies have the potential to revolutionize the surgical standard-of-care by enabling real-time detection of surgical margins, subclinical residual disease, lymph node metastases and synchronous/metachronous tumors. Fluorescence-guided surgery (FGS) in the near-infrared (NIRF) spectrum has shown tremendous promise as an intraoperative imaging modality. An increasing number of clinical studies have demonstrated that tumor-selective FGS agents can improve the predictive value of fluorescence over non-targeted dyes. Whereas NIRF-labeled macromolecules (i.e., antibodies) spearheaded the widespread clinical translation of tumor-selective FGS drugs, peptides and small-molecules are emerging as valuable alternatives. Here, we first review the state-of-the-art of promising low molecular weight agents that are in clinical development for FGS; we then discuss the significance, application and constraints of emerging tumor-selective FGS technologies. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8279813/ /pubmed/34277418 http://dx.doi.org/10.3389/fonc.2021.674083 Text en Copyright © 2021 Hernandez Vargas, Lin, Tran Cao, Ikoma, AghaAmiri, Ghosh, Uselmann and Azhdarinia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Hernandez Vargas, Servando Lin, Christie Tran Cao, Hop S. Ikoma, Naruhiko AghaAmiri, Solmaz Ghosh, Sukhen C. Uselmann, Adam J. Azhdarinia, Ali Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title | Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title_full | Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title_fullStr | Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title_full_unstemmed | Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title_short | Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents |
title_sort | receptor-targeted fluorescence-guided surgery with low molecular weight agents |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279813/ https://www.ncbi.nlm.nih.gov/pubmed/34277418 http://dx.doi.org/10.3389/fonc.2021.674083 |
work_keys_str_mv | AT hernandezvargasservando receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT linchristie receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT trancaohops receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT ikomanaruhiko receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT aghaamirisolmaz receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT ghoshsukhenc receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT uselmannadamj receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents AT azhdariniaali receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents |